BOSTON SCIENTIFIC CORP

BOSTON SCIENTIFIC CORP (BSX) — Investment Memo

🐂 The Bull Case (Warren's voice)

The beauty here isn't in the gadgetry; it's in the psychology of the practitioner.

• The "Muscle Memory" Moat: We aren't buying patents—which eventually expire—we are buying the habits of surgeons. Once a surgeon spends hundreds of hours mastering a BSX device, the cost of switching to a competitor is not financial; it is a risk to their clinical outcome and professional ego. That is a durable, compounding advantage.
• Operational Leverage: The numbers tell a story of efficiency. A Revenue CAGR of 9.5% paired with an FCF CAGR of 26.4% is a hallmark of a business that has found its scale. They are squeezing significantly more cash out of every dollar of sales.
• The Toll Bridge: By dominating specialized cardiovascular and surgical niches, BSX acts as a toll bridge for essential medical procedures. Demand is decoupled from the economic cycle—hearts don't stop beating because the S&P 500 is down.
• Attractive Entry: To warrant a Berkshire-sized position, we need the market to ignore the growth story and price this as a stagnant utility. We become genuinely interested when the price reflects a significant discount to the intrinsic value of the cash flows.

🐻 The Bear Case (Charlie inverts)

Show me where I'll die and I won't go there.

• The M&A Addiction: This isn't an organic compounder; it's a serial acquirer. If the "shopping spree" continues, they risk the "Winner's Curse"—overpaying for growth to mask a slowing internal R&D engine. If the cost of acquisition exceeds the return on invested capital (ROIC), they are destroying value while pretending to grow.
• The Paradigm Shift: The structural threat isn't a "better catheter"; it's the obsolescence of the procedure. If gene editing or non-invasive biologics render these surgical interventions redundant, the "patent thickets" become irrelevant. A moat doesn't matter if the castle is on an island that is sinking.
• The "2018 Stench": The total collapse of cash conversion in 2018 is a warning. While management may call it a "glitch," it reveals a vulnerability in their working capital or a capacity for massive one-time write-downs.
• Most Likely Threat: M&A Overreach. Over a 5-year horizon, the most likely failure is the integration of too many disparate targets, leading to a bloated corporate overhead and a dilution of the core culture.

💰 Valuation & Margin of Safety

The DCF is a baseline, not a mandate.

• Intrinsic value estimate: $88.31 per share
• 25% margin of safety entry: $66.23 (Conservative)
• 50% margin of safety entry: $44.16 (Buffett's ideal)
• Current Status: Expensive. Trading near or above the DCF estimate suggests the market has already priced in the 15% FCF growth. We are paying for perfection, leaving no room for the "M&A addiction" to fail.

Verdict: WATCH

The business is exceptional, but the price is an enthusiast's price, not an investor's price. We have high conviction in the "habit" moat, but we will not overpay for it. We wait for a market dislocation to bring the price toward $66.00.